Alto Neuroscience, Inc. (NYSE:ANRO) Receives $35.25 Consensus Target Price from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $35.25.

A number of research firms have weighed in on ANRO. Bank of America initiated coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective on the stock. Wolfe Research initiated coverage on shares of Alto Neuroscience in a report on Friday. They issued an “outperform” rating on the stock. JonesTrading cut their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Alto Neuroscience in a report on Monday, May 11th. Finally, BTIG Research lifted their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors have recently modified their holdings of the business. Commodore Capital LP increased its holdings in shares of Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after acquiring an additional 900,000 shares during the period. Vestal Point Capital LP increased its stake in Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after buying an additional 1,535,000 shares during the period. Perceptive Advisors LLC raised its position in Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after buying an additional 1,629,027 shares during the last quarter. Armistice Capital LLC lifted its stake in shares of Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares during the period. Finally, Spruce Street Capital LP lifted its stake in shares of Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after acquiring an additional 1,102,366 shares during the period.

Alto Neuroscience Stock Down 0.7%

ANRO stock opened at $21.08 on Wednesday. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a twelve month low of $2.15 and a twelve month high of $28.44. The company’s 50 day moving average is $23.16 and its two-hundred day moving average is $18.94. The stock has a market cap of $739.78 million, a P/E ratio of -8.71 and a beta of 1.62.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Research analysts expect that Alto Neuroscience will post -2.98 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.